RIOX2

Across TCGA pan-cancer cohorts, RIOX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RIOX2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RIOX2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RIOX2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where RIOX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	1.000	0.801	.005	16	view →
HNSC	DFS	Median	All	0.914	0.987	.005	10	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	3	view →
GBM	OS	Median	All	0.585	0.479	.033	3	view →
LUAD	DFS	Median	All	0.717	0.550	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RIOX2–LSCC (DFS)

Open the LSCC breakdown →